Years of life lost due to deaths of despair and COVID-19 in the United States in 2020: patterns of excess mortality by gender, race and ethnicity.

BACKGROUND: In 2020 COVID-19 was the third leading cause of death in the United States. Increases in suicides, overdoses, and alcohol related deaths were seen-which make up deaths of despair. How deaths of despair compare to COVID-19 across racial, ethnic, and gender subpopulations is relatively unknown. Preliminary studies showed inequalities in COVID-19 mortality for Black and Hispanic Americans in the pandemic's onset. This study analyzes the racial, ethnic and gender disparities in years of life lost due to COVID-19 and deaths of despair (suicide, overdose, and alcohol deaths) in 2020. METHODS: This cross-sectional study calculated and compared years of life lost (YLL) due to Deaths of Despair and COVID-19 by gender, race, and ethnicity. YLL was calculated using the CDC WONDER database to pull death records based on ICD-10 codes and the Social Security Administration Period Life Table was used to get estimated life expectancy for each subpopulation. RESULTS: In 2020, COVID-19 caused 350,831 deaths and 4,405,699 YLL. By contrast, deaths of despair contributed to 178,598 deaths and 6,045,819 YLL. Men had more deaths and YLL than women due to COVID-19 and deaths of despair. Among White Americans and more than one race identification both had greater burden of deaths of despair YLL than COVID-19 YLL. However, for all other racial categories (Native American/Alaskan Native, Asian, Black/African American, Native Hawaiian/Pacific Islander) COVID-19 caused more YLL than deaths of despair. Also, Hispanic or Latino persons had disproportionately higher mortality across all causes: COVID-19 and all deaths of despair causes. CONCLUSIONS: This study found greater deaths of despair mortality burden and differences in burden across gender, race, and ethnicity in 2020. The results indicate the need to bolster behavioral health research, support mental health workforce development and education, increase access to evidence-based substance use treatment, and address systemic inequities and social determinants of deaths of despair and COVID-19.

Pain and its Perceived Relatedness to the Onset, Maintenance, and Relapse of Opioid use Disorder: A Descriptive Study of Non-Treatment-Seeking Individuals.

Background: Previous research has found chronic pain to be prevalent among individuals with opioid use disorder (OUD). The perception that pain is related to OUD onset, maintenance, relapse, and treatment delay has been noted in this population. However, prior works primarily involved treatment-engaged populations. Scant research describes such perceptions among non-treatment-seeking individuals. Aims: This study describes pain burden and perceptions regarding the role of pain in OUD onset, maintenance, relapse, and addiction treatment delay in a sample of individuals with untreated OUD. Methods: This cross-sectional study surveyed syringe exchange participants (n = 141). Participants responded to a survey including Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition OUD criteria, pain survey scales, demographic characteristics, and questions regarding pain and its perceived relatedness to aspects of OUD. Results: Most participants reported pain within the past 4 weeks (127, 91.4%). Data displayed a skew toward more intense pain ratings, with 120 reporting their pain as greater than mild (86.3%). A majority of participants agreed that pain was responsible for their OUD onset (79, 56.4%), maintenance (76, 54.3%), past relapse experience (82, 57.9%), and treatment delay (81, 57.9%). Correlative analyses revealed that pain severity and interference measures displayed moderate and statistically significant associations with extent of perceived relatedness of pain to these aspects of OUD. Conclusions: Among this sample of individuals with untreated OUD, pain and pain interference were prevalent. Pain was perceived to be related to OUD onset, maintenance, relapse, and treatment delay by a majority of the sample. These findings are in accordance with and expand upon prior works. Abbreviations: OUD: opioid use disorder; DSM-5: Diagnostic and Statistical Manual 5; BPI: Brief Pain Inventory; NIDA: National Institute on Drug Abuse; IASP: International Association for the Study of Pain; MOUD: Medications for Opioid Use Disorder; IQR: Interquartile Range.

Contexte: Des recherches antérieures ont montré que la douleur chronique est prévalente chez les personnes souffrant d'un trouble lié à l'utilisation d'opioïdes (TUO). La perception que la douleur est liée à l'apparition, au maintien, à la rechute et au retard dans le début du traitement a été constatée au sein de cette population. Toutefois, les travaux antérieurs portaient principalement sur les populations engagées dans un traitement. Peu de recherches décrivent ces perceptions chez les personnes qui ne sont pas à la recherche d'un traitement.Objectifs: Cette étude décrit le fardeau de la douleur et les perceptions concernant le rôle de la douleur dans l'apparition, le maintien, la rechute et le retard dans le début du traitement du trouble lié à l'utilisation d'opioïdes chez un échantillon de personnes souffrant d'un trouble lié à l'utilisation d'opioïdes non traité.Méthodes: Cette étude transversale a interrogé des participants pratiquant l'échange de seringues (n = 141). Les participants ont répondu à un questionnaire comprenant les critères de la cinquième édition du Manuel diagnostique et statistique des troubles mentaux pour le trouble lié à l'utilisation d'opioïdes, des échelles d'évaluation de la douleur, leurs caractéristiques démographiques, ainsi que des questions concernant la douleur et son lien perçu avec différents aspects du trouble lié à l'utilisation d'opioïdes.Résultats: La plupart des participants ont déclaré avoir ressenti de la douleur au cours des quatre dernières semaines (127, 91,4 %). Les données ont montré une tendance à évaluer la douleur de façon plus intense, 120 participants ayant déclaré que leur douleur était plus que légère (86,3 %). La majorité des participants ont reconnu que la douleur était responsable de l'apparition (79, 56,4 %), du maintien (76, 54,3 %), des rechutes antérieures (82, 57,9 %) et du retard dans le début du traitement (81, 57,9 %) du trouble lié à l'utilisation des opioïdes. Les analyses corrélatives ont révélé que les mesures de l'intensité et de l'interférence de la douleur présentaient des associations modérées et statistiquement significatives avec l'étendue du lien perçu entre la douleur et ces aspects du trouble lié à l'utilisation des opioïdes.Conclusions: Dans cet échantillon de personnes atteintes d'un trouble lié à l'utilisation des opioïdes non traité, la douleur et l'interférence de la douleur étaient prévalentes. La douleur était perçue comme étant liée à l'apparition, au maintien, à la rechute et au retard dans le début du traitement du trouble lié à l'utilisation des opioïdes par la majeure partie de l'échantillon. Ces résultats sont conformes aux travaux antérieurs et les étayent.Abréviations: TUO : trouble lié à l'utilisation d'opioïdes; DSM-5 : Manuel diagnostique et statistique 5; BPI : Questionnaire concis sur la douleur; NIDA : National Institute on Drug Abuse; IASP : Association internationale pour l'étude de la douleur; MTUO : Médicaments pour le trouble lié à l'utilisation des opioïdes; EIQ : Écart interquartile.

Fibromyalgia predicts increased odds of pain-related addiction exacerbation among individuals with pain and opioid use disorder.

ABSTRACT: Fibromyalgia and opioid use disorder (OUD) are highly impactful chronic illnesses with substantially overlapping psychosocial, biological, and clinical features. Little previous research has examined interactions between fibromyalgia and OUD. Limiting such research has been the previous requirement of a clinical examination to diagnose fibromyalgia. The 2011 American College of Rheumatology Fibromyalgia Survey (ACR-FMS) is a validated self-report instrument with high sensitivity and specificity for fibromyalgia intended to enable fibromyalgia research in settings where a clinical examination is impractical. The present observational study uses the ACR-FMS to determine whether fibromyalgia affects odds of acknowledging pain-related OUD exacerbations among a sample of participants with pain and OUD. Participants with pain and OUD (n = 125) were recruited from an academic substance use treatment facility. The ACR-FMS, along with an original scale measuring pain-related OUD exacerbation-the Pain-related OUD Exacerbation Scale-was administered through an electronic survey. The factor structure, internal consistency, and construct validity of Pain-related OUD Exacerbation Scale were tested. In addition, descriptive analyses, multiple hierarchical linear regression, ordinal logistic regression, and multinomial logistic regression analyses were performed. Although all participants had pain, those with fibromyalgia demonstrated significantly greater odds of acknowledging pain-related OUD exacerbations. Pain-related OUD Exacerbation Scale was found to have a single-factor solution, strong internal consistency, and construct validity. This study provides first evidence of fibromyalgia as a risk factor for pain-related exacerbation of OUD and introduces a new scale with promising psychometric properties to measure pain-related OUD exacerbation.

Untreated Opioid Use Disorder and Health-Related Quality of Life Among Syringe Service Program Clients.

This cross-sectional study explores health-related quality of life (HRQoL) and the challenges to physical, emotional, and social functioning among individuals with opioid use disorder.

Years of Life Lost to Firearm Suicide Among Young People in the US.

This cross-sectional study examines years of life lost among the top 3 causes of death and compares firearm suicide with other methods of suicide among individuals aged 10 to 24 years in the US.